ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)

ASCO 2024 results of a multicenter phase II trial of modified FOLFIRINOX for the first-line treatment of advanced urachal cancer (ULTMA; KCSG GU20-03), Urachal cancer is a rare malignancy accounting for 1% of bladder cancers.

Related Keywords

Chicago ,Illinois ,United States ,Toronto ,Ontario ,Canada ,South Korea ,Seoul ,Soult Ukpyolsi ,American ,Jae Lyun Lee ,Md Anderson Cancer Center ,Society Of Urologic Oncology ,American Society Of Clinical Oncology ,Twitter ,University College Of Medicine ,Asan Medical Center ,University Of Toronto ,Clinical Oncology ,Annual Meeting ,University College ,Rashid Sayyid ,Urologic Oncology ,Clinical Fellow ,Anderson Cancer Center ,Patients With Relapsed ,Metastatic Malignant Urachal ,